Surgeon general nominee's confirmation hearing postponed due to unexpected labor, prolonging vacancy in top public health post.
Cash-rich stocks show mixed growth and risks, with some companies facing stagnation, poor reinvestment, and margin erosion, while others leverage strong balance sheets and momentum.
Proxy adviser ISS recommends rejecting CoreWeave's $9 billion bid to acquire Core Scientific, citing concerns over the "rushed sale process" and "fixed exchange ratio" that undervalue Core Scientific.
Surgeon general nominee's confirmation hearing postponed due to unexpected labor, prolonging vacancy in top public health post.
Cash-rich stocks show mixed growth and risks, with some companies facing stagnation, poor reinvestment, and margin erosion, while others leverage strong balance sheets and momentum.
Proxy adviser ISS recommends rejecting CoreWeave's $9 billion bid to acquire Core Scientific, citing concerns over the "rushed sale process" and "fixed exchange ratio" that undervalue Core Scientific.